Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (Nasdaq: CCCC) is a pioneering clinical-stage biopharmaceutical company focused on utilizing targeted protein degradation to create novel medicines that transform patient outcomes. The company's core technology, the TORPEDO® platform, enables the design and optimization of small-molecule medicines aimed at degrading disease-causing proteins through the ubiquitin/proteasome system. This innovative approach offers solutions to overcome drug resistance and target previously undruggable proteins.
C4 Therapeutics is actively advancing several proprietary oncology programs into clinical trials. Notable among these is CFT7455, also known as cemsidomide, an oral degrader targeting IKZF1/3 for treating relapsed/refractory multiple myeloma (R/R MM) and non-Hodgkin’s lymphomas (R/R NHL). Recent clinical data indicates that CFT7455 is well-tolerated and exhibits promising anti-myeloma activity, supporting its continued development.
Another key program, CFT1946, is an oral BiDAC™ degrader designed to target BRAF V600 mutations. This compound is being tested for its efficacy in treating solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma. Early clinical results are promising, showing that CFT1946 is active against BRAF V600E-driven disease and exhibits central nervous system (CNS) activity, a significant advantage over existing BRAF inhibitors.
In addition to its internal programs, C4 Therapeutics has established strategic partnerships with industry leaders such as Roche, Biogen, and Merck KGaA, Darmstadt, Germany. These collaborations aim to leverage the company's TORPEDO® platform to discover and develop new degraders targeting various oncogenic proteins. Notably, under an agreement with Merck KGaA, C4T will receive an upfront payment and significant milestone payments, underpinning the potential commercial success of their partnered programs.
Financially, C4 Therapeutics reported a total revenue of $20.8 million for 2023, with a net loss of $132.5 million. However, the company is well-capitalized, with cash, cash equivalents, and marketable securities amounting to $281.7 million as of December 31, 2023, ensuring sufficient funds to support its operations into 2027.
By continuously pushing the boundaries of targeted protein degradation science, C4 Therapeutics aims to revolutionize the treatment landscape for patients with challenging diseases, ultimately striving to deliver breakthrough therapies that significantly enhance patient care and outcomes.
C4 Therapeutics, a biopharmaceutical company, reported strong financial results for the first quarter of 2024. They earned an $8 million payment from Biogen, established a research collaboration with Merck KGaA, and advanced Phase 1 trials for CFT7455 and CFT1946. The company's cash position stood at $299.2 million, providing runway into 2027.
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
What is the core technology of C4 Therapeutics?
What are the main focus areas of C4 Therapeutics’ current projects?
Who are some of C4 Therapeutics’ strategic partners?
What were C4 Therapeutics’ financial results for 2023?
What is CFT7455, also known as cemsidomide?
What is unique about CFT1946?
How does C4 Therapeutics’ technology address drug resistance?
What recent partnerships has C4 Therapeutics announced?
What are the cash and financial projections for C4 Therapeutics?
Where can I find more information about C4 Therapeutics' clinical trials?
